摘要
目的观察孟鲁司特钠咀嚼片辅助治疗儿童支气管肺炎的临床效果。方法92例儿童支气管肺炎患儿,采用随机数字表法分为对照组与观察组,各46例。对照组采取常规治疗方法进行治疗,观察组在对照组基础上加服孟鲁司特钠咀嚼片进行治疗。比较两组患儿的治疗效果、临床症状消失时间、住院时间、治疗后C反应蛋白(CRP)水平以及不良反应发生情况。结果观察组总有效率为91.3%,高于对照组的76.1%,差异有统计学意义(P<0.05)。观察组咳嗽咳痰、呼吸急促气喘、肺部啰音消失时间及住院时间分别为(4.83±1.20)、(4.74±1.16)、(5.07±0.98)、(7.43±0.72)d,均短于对照组的(6.35±1.57)、(5.74±1.08)、(6.63±1.29)、(8.46±1.07)d,差异有统计学意义(P<0.05)。治疗前,对照组CRP水平为(18.84±5.25)mg/L,观察组CRP水平为(19.27±5.43)mg/L,比较差异无统计学意义(P>0.05);治疗后,对照组CRP水平为(7.05±2.07)mg/L,观察组CRP水平为(5.89±3.01)mg/L,两组CRP水平均显著低于本组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组患儿在药物治疗过程中均未发生明显的不良反应。结论对支气管肺炎患儿采取孟鲁司特钠咀嚼片进行辅助治疗,可有效缓解咳嗽咳痰及喘息等症状,并降低患儿炎症反应,疗效确切,不良反应少,有积极的临床意义。
Objective To observe the clinical effect of montelukast sodium chewable tablets in adjuvant treatment of bronchopneumonia in children. Methods A total of 92 children with bronchopneumonia were divided into control group and observation group according to random number table method, with 46 cases in each group. The control group was treated with conventional therapy, and the observation group was treated with montelukast sodium chewable tablets on the basis of the control group. Comparison was made on therapeutic effect, disappearance time of clinical symptoms, hospitalization time, C-reactive protein(CRP) after treatment and occurrence of adverse reactions between the two groups. Results The total effective rate of treatment was 91.3% in the observation group, which was higher than 76.1% in the control group, and the difference was statistically significant(P<0.05). The disappearance time of cough and sputum, shortness of breath and asthma and lung rales and hospitalization time were(4.83±1.20),(4.74±1.16),(5.07±0.98) and(7.43±0.72) d respectively in the observation group, which was shorter than(6.35±1.57),(5.74±1.08),(6.63±1.29) and(8.46±1.07) d in the control group, and their difference was statistically significant(P<0.05). Before treatment, the CRP was(18.84±5.25) mg/L in the control group, which was(19.27±5.43) mg/L in the observation group, and the difference was not statistically significant(P>0.05). After treatment, the CRP was(7.05±2.07) mg/L in the observation group, which was(5.89±3.01) mg/L in the control group. The CRP after treatment in the two groups was significantly lower than those before treatment, and the observation group was lower than the control group. Their difference was statistically significant(P<0.05). There were no obvious adverse reactions during treatment in both groups. Conclusion The adjuvant therapy of montelukast sodium chewable tablets shows affirmative efficacy for children with bronchopneumonia, and it can effectively relieve the symptoms of cough, sputum and whe
作者
宋和娣
孟凡成
钱前
鲍华
SONG He-di;MENG Fan-cheng;QIAN Qian(Lianyungang Maternal and Child Health Hospital,Lianyungang 222006,China)
出处
《中国现代药物应用》
2019年第21期11-13,共3页
Chinese Journal of Modern Drug Application
关键词
儿童支气管肺炎
孟鲁司特钠咀嚼片
白三烯
不良反应
Bronchopneumonia in children
Montelukast sodium chewable tablets
Leukotriene
Adverse reactions
